Assembly Biosciences (ASMB) Expected to Announce Earnings on Monday

Key Points

• Assembly Biosciences is expected to report Q3 2026 results after the market closes Monday, November 9. Analysts forecast a loss of $0.655 per share and revenue of $9.07 million.
• The company’s previous quarter exceeded expectations, reporting a $0.20 per-share loss versus the $0.72 consensus loss and revenue of $13.37 million versus estimates of $8.60 million.
• Shares opened at $20.13, near their 12-month low of $19.30 and below their 50-day and 200-day moving averages. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $47.50.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Assembly Biosciences to announce earnings of ($0.6550) per share and revenue of $9.07 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. On average, analysts expect Assembly Biosciences to post $2.28 EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

Assembly Biosciences Price Performance

Assembly Biosciences stock opened at $20.13 on Monday. The company has a 50 day moving average of $26.14 and a 200-day moving average of $27.24. The stock has a market capitalization of $409.85 million, a PE ratio of 19.74 and a beta of 1.26. Assembly Biosciences has a twelve month low of $19.30 and a twelve month high of $39.71.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. UBS Group began coverage on shares of Assembly Biosciences in a research report on Tuesday, September 1st. They issued a "buy" rating and a $52.00 price objective on the stock. Zacks Research raised Assembly Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday, August 18th. Finally, Mizuho set a $53.00 target price on Assembly Biosciences in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $47.50.

About Assembly Biosciences

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company's research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control.

Assembly's pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.